Entrada Therapeutics announced its third‑quarter 2025 financial results on November 6, 2025. The company posted a net loss of $44.1 million, a sharp rise from the $14.0 million loss reported in the prior quarter. Collaboration revenue for the quarter was $1.6 million, down from $19.6 million in the same period last year, reflecting the completion of the research plan for its Vertex partnership.
The company’s cash, cash equivalents and marketable securities stood at $326.8 million as of September 30, 2025, a decline from $420.0 million at the end of 2024. Management projects that this balance will support operations through the third quarter of 2027, extending the company’s runway by roughly two years compared to the previous quarter’s outlook.
Entrada’s higher R&D expense of $38.4 million (up from $31.3 million) and G&A expense of $10.3 million (up from $10.0 million) underscore the company’s intensified investment in its Duchenne muscular dystrophy franchise. The company also highlighted that it expects to have three clinical‑stage programs—ENTR‑601‑44, ENTR‑601‑45 and ENTR‑601‑50—by year‑end, positioning it for future data releases and potential regulatory submissions in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.